尊龙凯时人生就是搏·(中国区)官方网站
About Us
About Sino Biopharm
Board of Directors
Senior Management
R&D
R&D Team
Products
Product List
Sustainability
ESG Governance
ESG Management Practices
ESG Reports
Investors
Information Disclosure
Corporate Governance
Presentation
Investor FAQ
Notices
News
Press Releases
Contact
CN
EN
Investors
Home
>
Investors
>
Information Disclosure
Information Disclosure
Corporate Governance
Presentation
Investor FAQ
Notices
Information Disclosure
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB FOR FIRST-LINE TREATMENT OF SQ-NSCLC PRESENTED IN 2025 ASCO ANNUAL MEETING
2025.05.23
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2025
2025.05.06
2024 ANNUAL REPORT
2025.04.29
GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; ADOPTION OF THE NEW ARTICLES; AND NOTICE OF ANNUAL GENERAL MEETING
2025.04.29
NOTICE OF ANNUAL GENERAL MEETING
2025.04.29
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF)
2025.04.29
NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED SHAREHOLDERS
2025.04.29
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS
2025.04.29
首页
上一页
1
2
3
4
5
6
...
55
尾页
下一页